Caroline Stout - Profile and Investment Details

Investor Profile

Caroline Stout is a Venture Capital, Private Equity Firm based in San Francisco, California, United States with a diverse investment portfolio that includes companies such as Notch Therapeutics, Magenta Therapeutics, Syros Pharmaceuticals, Eledon Pharmaceuticals, Peloton Therapeutics, Ardelyx, Atara BiotherapeuticsNabriva Therapeutics, Silverback Therapeutics, Metacrine, Prevail Therapeutics, Nuvation Bio, Editas Medicine, Relay Therapeutics, Aktis Oncology, Neurogene, Inc., Freenome, Scorpion Therapeutics, Avidity Biosciences, Alpine Immune Sciences, Naurex, Dicerna Pharmaceuticals, Flex Pharma, Morphic Therapeutic, ElevateBio, Surface Oncology, Collegium Pharmaceutical, Affinivax, Codiak Biosciences, Neogene Therapeutics, UNITY Biotechnology, Intellia Therapeutics, Ashvattha Therapeutics, Pieris Pharmaceuticals, Atreca, AlloVir, ORIC Pharmaceuticals, Scholar Rock, Dewpoint Therapeutics, Clementia Pharmaceuticals, Accent Therapeutics, Solid Biosciences, Centessa Pharmaceuticals, Kronos Bio, Chinook Therapeutics, Artiva Biotherapeutics, Akouos, Gritstone Oncology, aTyr Pharma, Kura Oncology, Kezar Life Sciences, Arcus Biosciences, Affinia Therapeutics, Accent Therapeutics, Inc. , Nurix Therapeutics, Syndax Pharmaceuticals, Cellares, Shattuck Labs, Neurogene, SAGE Therapeutics, . Over time, Caroline Stout has demonstrated experience in supporting a range of businesses across various sectors.

While it is not publicly confirmed whether Caroline Stout is currently seeking new investment opportunities, their past investments provide valuable insight into the types of projects and industries that have attracted their attention.

Startups and entrepreneurs operating in sectors related to Health Care, Wellness, Investment Management, Android, Life Science, Engineering, Portfolio Management, Finance, Software, Biotechnology, Drug Development, Productivity Software, Consulting, Health Diagnostics, Developer Tools, Medical, B2B, Therapeutics, Financial Advisory, Media and Entertainment, Pharmaceuticals may find it worthwhile to explore potential connections with Caroline Stout, as their portfolio suggests a familiarity and interest in this area.

Understanding Caroline Stout’s investment history can offer useful context for founders considering outreach and help identify whether there is a potential fit based on strategic alignment and market focus.